RenovoRx, Inc. aksje
RNXT
Sanntid$0.8952-0.0153 (-1.68%)
Laster graf...
RenovoRx, Inc.
Market Cap
$40,372,744
Åpning0.9009
Høy0.9204
Lav0.8700
Volum84.48k
P/EN/A
Markedsverdi40.37M
52-ukers høy1.4500
52-ukers lav0.7010
Gj.sn. volum374.34k
UtbytteN/A
BetaN/A
EPS-0.3300
Om RenovoRx, Inc. aksje
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Selskapsinformasjon
Børs: NasdaqCM (NCM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
2570 West El Camino Real
94040 Mountain View, United States
94040 Mountain View, United States
Telefon: + 650 284 4433
Nettside: https://renovorx.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Laveste kursmål
3.00
↑ 235.1%
Gjennomsnittlig kursmål
7.03
↑ 685.3%
Median kursmål
5.56
↑ 521.1%
Høyeste kursmål
14.00
↑ 1463.9%